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Previous studies demonstrating increased adrenergic tone
in symptomatic patients with mitral valve prolapse
prompted a study of the response of symptomatic pa-
tients with mitral valve prolapse to adrenergic stimu-
lation. Sixteen such patients had plasma catecholamines
and 24 hour urinary epinephrine plus norepinephrine
values that were greater than those of control subjects
(473.3 ± 92.8 pg/ml versus 292 ± 15 and 44.7 ± 2.3
ILg/g creatinine versus 29.8 ± 2.3; P < 0.01 and < 0.001,
respectively). Twenty-four hour urinary sodium was lower
in the patient group than in the control group (75 ± 7.4
versus 141 ± 11 mEq; p < 0.01), with an inverse relation
between urinary sodium and norephinephrine in the pa-
tient group (r =- 0.78) but not in the control group.
Isoproterenol infusions, 0.5, 1.0 and 2.0 ILg/min for
6 minutes, produced a dose-related, greater increase in
heart rate in the mitral valve prolapse group than in the
control group (16.1 ± 2.3 versus 10 ± 2; 31.8 ± 3.5
versus 19.6 ± 3; 48 ± 4.1 versus 27 ± 3; p< 0.01 with
0.5, 1.0 and 2.0 ILg, respectively). The greater increase
Symptomatic patients with mitral valve prolapse, currently
referred to as the mitral valve prolapse syndrome, may pres-
ent with anxiety, tachycardia, neurasthenia, arrhythmias,
chest pain and posture-related phenomena (1-8). The auto-
nomic nervous system has long been postulated as a potential
source for these symptoms. Recent evidence (8-12) sug-
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in heart rate resulted in a significantly shorter diastolic
time in the patient group than in the control group (26.4
± 2 s/min versus 30.6 ± 2; 27 ± 1.5 versus 30.6 ± 2;
26.6 ± 2 versus 30.9 ± 2; p < 0.01 with 0.5, 1.0 and
2.0 ILg, respectively). The QT interval was 25 ms shorter
than electromechanical systole (QS2) in the normal group
and 26.5 ms shorter than QS2in the mitral valve prolapse
group at rest; during isoproterenol infusion QT-QS2val-
ues were different in the mitral valve prolapse and con-
trol groups (3.3 ± 3 versus -7.0 ± 3; 31.9 ± 2.8 versus
10 ± 4; 52 ± 9.2 versus 29 ± 8; p < 0.01 with 0.5,
1.0 and 2.0 ILg/min,respectively). Isoproterenol infusion
also reproduced symptoms on a dose-related basis in 14
patients with mitral valve prolapse but not in control
subjects (excluding palpitation).
Symptomatic patients with mitral valve prolapse and
high rest values of catecholamines were hypersensitive
to isoproterenol infusion, suggesting that some of the
symptoms are catecholamine-related or mediated.
gests that autonomic dysfunction, a hyperadrenergic state,
or combinations thereof, associated with or occurring in the
presence of mitral valve prolapse are a potential explanation
for the diversity of behavior and clinical manifestations in
the mitral valve prolapse syndrome.
We consider the mitral valve prolapse syndrome to be a
constitutional neuroendocrine-cardiovascular process, Partly
as a result of our earlier studies (10) showing that patients
with this syndrome had high rest adrenergic activity, studies
by other investigators (8,11,12) who presented evidence of
autonomic dysfunction in patients with the mitral valve pro-
lapse syndrome and, in particular, the many clinical obser-
vations during the past 120 years suggesting that individuals
with irritable heart, soldier's heart and neurocirculatory as-
thenia had disorders of the sympathetic nervous system as
a basis for their symptoms (1), the present study was un-
dertaken to investigate the effect of adrenergic stimulation
in symptomatic patients with mitral valve prolapse.
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Methods
Study patients. Sixteen symptomatic patients, 12 women
with an age range of 21 to 54 years (mean ± standard
deviation 35 ± 10,5) and 4 men ranging in age from 32 to
41 years (mean 38.5 ± 2.65) with auscultatory, phono-
cardiographic and echocardiographic findings of mitral valve
prolapse were studied (2-5, 13- 15). Symptoms included chest
pain (II patients), palpitations, or irregular beats (10 pa-
tients), fatigue (8 patients), dyspnea (6 patients) and diz-
ziness (3 patients). Auscultatory findings included a mid-
systolic click and late systolic murmur in 13 patients and a
mid-systolic click in 3 patients (4). Five of the patients
participated in our previous study (10 ). Informed written
consent was obtained from each patient according to a pro-
tocol approved by the Institutional Human Research Com-
mittee,
Protocol. The patients were admitted to the ClinicalRe-
search Center to standardize the environmental stimulation
and placed on a caffeine-free, ad lib sodium diet. Medi-
cations were discontinued at least I week (beta-blocking
agents at least 3 weeks) before the study. During hospital-
ization, the following procedures were performed:
Day J. Epinephrine, norephinephrine and sodium were
measured in a 24 hour urine specimen.
Day 2. Twenty-four hour urinary epinephrine, norepi-
nephrine and sodium measurements were repeated. A phon-
ocardiogram, systolic time interval determinations and M-
mode echocardiogram were performed between 10:00 and
II :00 a.m. Serial isoproterenol infusions were performed
between 12:00and I:00 p.m. A maximal treadmillexercise
test was performed between 2:00 and 3:00 p.m. Forty-five
to 60 minutes before the exercise, a heparinized needle was
insertedin a forearm vein. After the patienthad been supine
for 30 minutes, blood was drawn for the preexercise plasma
epinephrine , norepinephrine and total plasmacatecholamine
measurements. The patient then completed the exercise pro-
tocol. Immediately thereafter, with the patientagain supine,
bloodwasdrawn for a postexercise plasmaepinephrine , nor-
epinephrine and total plasma catecholamine determination.
Day 3. Twenty-four hour urinary epinephrine . norepi-
nephrine and sodium measurements were repeated.
Day 4. Twenty-four hour urinary epinephrine, norepi-
nephrine and sodium measurements were repeated. In ad-
dition, 24 hour ambulatory monitoring was performed.
Systolic time intervals and echocardiograms were ob-
tained using standard techniques (13-18).
Measurements. The duration of electrical systole (QT)
and electromechanical systole (QSz) was measured from the
simultaneous recordings of the electrocardiogramand phon-
ocardiogram at a paper speed of 100 mmls. The QSz in-
terval was measured from the onset of ventricular depolar-
ization to the first high frequency vibration of the aortic
componentof the second heart sound. The QT interval was
measured from the beginning of the Q wave to the end of
the T wave. In rare instances when the end of the T wave
was not precise, the end of the T wave was taken at the
point where a line of most rapid descent of the T wave
transccted the baseline. At least 10 cardiac cycles were
averaged to obtain the QSz and QT intervals (19). Diastolic
time was measuredfrom the cardiac cycle length (RR), sub-
tracting the total electromechanical systolic time (QSz) (20).
Maximal treadmill exercise testing was perfomed ac-
cording to the Bruce protocol (21.22). Heart rate was in-
creased by at least 100% in all patients during exercise.
Twenty-four ambulatory electrocardiographic recordings were
obtained witha portablecassette tape (Avionics model600).
The data were analyzed by playback (Avionics model 445)
as described previously (22).
Urinary epinephrineand norepinephrine were measured
fluorometrically (23). The interassay coefficient of variation
was 13.4 % for epinephrine, 12.8% for norepinephrine and
10.7% for totalcatecholamines. Plasma catecholamine mea-
surements were performed according to the method of Pas-
son using a single isotope assay (24) . The interassay coef-
fic ient of variation was 12.6%. Urinary creatinine measured
by the Jaffee reaction had a coefficient of variation of 2.2%
(25) .
Isoproterenol infusion protocol. After 30 minutes of
recumbent rest, normal saline solution was infused for 30
minutes. Then 6 minute isoproterenol infusions of 0.5, 1.0
and 2.0 }Lg/min were alternated with normal saline solution
infusions using a Harvard infusion pump. This duration of
isoproterenol infusion was based on a previous study (26)
in which serial measurements helped establish that a steady
state is reached after 6 minutes of isoproterenol infusion.
Changes in heart rate, blood pressure, relation between QT
and QSz intervals and diastolic time were analyzed before
and during each isoproterenol infusion; the patient's symp-
toms were recorded for each infusion.
Control groups. Control values for 24 hour urinary ep-
inephrine. norepinephrine and sodium excretion levels were
obtained from29 normalambulatorysubjects (24 womenand
5 men, mean age 32.1 ± 4 years) in no obvious stress (10).
Inaddition. 35 hospitalized patients (23 women and 12 men.
mean age 39 ± 6 years)with normal cardiovascular function
undergoing minimally stressful diagnostic studies were used
as control subjects for epinephrine and norepinephrine de-
terminations (10). Control values for plasma epinephrine
and norepinephrine were obtained from 30 normal ambu-
latory subjects. The ages of control patients were compa-
rable with those of patients with mitral valve prolapse syn-
drome. Postexercise values were obtained with maximal
treadmillexercise. Heart rate was increased by at least 100%
in all subjects. Control values for changes due to isopro-
terenol infusion were obtained from 12 normal volunteers
without cardiovascular disease and no obvious stress in whom
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Figure I. Twenty-fourhoururinaryepinephrine (E), norepineph-
rine (NE) and epinephrine plus norepinephrine excretion. Patients
with mitral valve prolapse syndrome (MVPS) had higher levels
than did normal control subjects.
isoproterenol infusions were performed during their admis-
sion in the Clinical Research Center for 2 days.
Statistical evaluation was performed using the Student' s
t test and analysis of variance.
NE TOTAL
AFTER
EE
1500 NS NS
D CONTROL
(n :30)
MVPS
(n : 101
1000
~
'"c,
p cOOO I
500 peO.OI
Isoproterenol Infusions
Heart rate and pulse pressure (Fig. 4). Baseline heart
rate and pulse pressure measurements were not significantly
different in symptomatic patientswith mitral valve prolapse
compared with control subjects (74 ± 2.6 versus 71 ± 5
beats/min and 49. 1 ± 2.2 versus 53 ± 3 mm Hg, respec-
tively). During isoproterenol infusion, the increase in heart
rate and pulse pressure was dose-related. The increase in
heart rate during isoproterenol infusion was significantly
greater in symptomatic patients with mitral valve prolapse
compared with normal control subjects, whereas changes in
Figure2. Plasma epinephrine (E), norepinephrine (NE) and total
plasma catecholamines before exercise were significantly higher
in patients withmitralvalve prolapsesyndrome (MVPS)compared
with control subjects but were not different immediately after
exercise.
symptomatic patients with mitral valve prolapse compared
with normal control subjects (Fig. 2). These values did not
differ immediately after exercise in the two groups. In-
creased 24 hour urinary epinephrine and norepinephrine ex-
cretion and high plasma catecholamines have been reported
previously from this institution in another separate study
(10) involving 20 symptomatic patients with mitral valve
prolapse.
Urinary sodium excretion. Twenty-four hour urinary
sodium excretion was lower in patients with mitral valve
prolapse compared with control subjects (75 ± 7.4 versus
141 ± II mEq, p < 0.01) . There was an inverse correlation
between urinary norepinephrine and urinary sodium excre-
tion for patients with mitral valve prolapse (r = - 0.78)
but not for control subjects (r = - 0.05) (Fig. 3). The 24
hour sodium excretion was not significantly different in the
study patients from day to day during the hospitalization
period. There was no relation between urinary epinephrine
and urinary sodium excretion, and plasma norepinephrine
and urinary sodium excretion in patients with mitral valve
prolapse.
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Results
Noninvasive cardiac tests. All patients had normal left
ventricular systolic function as measured by systolic time
intervals and echocardiography, and normal left and right
ventricular and left atrial sizes as determined by echocardi-
ography. Six patients had a normal electrocardiogram, six
had nonspecific ST and T wave changes, two had right
bundle branch block, one had increased anterior forces and
one had premature ventricular beats. During the 24 hour
ambulatory monitoring period, frequent premature ventric-
ular beats (> W/min) were recorded in five patients, oc-
casional premature ventricular beats were recorded in two
patients and atrial tachycardia was recorded in one patient.
In two patients, inappropriate sinus tachycardia (140 to 150
beats/min) was recorded with minimal physical activity.
Urinary and plasma epinephrine plus norepineph-
rine . The 24 hour urinary excretion of epinephrine, nor-
epinephrine and epinephrine plus norepinephrine were sig-
nificantly higherinpatients than innormalambulatory control
subjects (44.7 ± 2.3 I-'-g/g creatinine versus 29.8 ± 2.3
for combined epinephrine plus norepinephrine) (Fig. I). In
addition, combined 24 hour urinary epinephrine and nor-
epinephrine excretion was significantly higher (probability
Ip] < 0.001) in the study patients than in the 35 hospitalized
patients used as control subjects (44.7 ± 2.3 versus 31.2
± 2 I-'-g/g creatinine). The 24 hour epinephrine, norepi-
nephrine and epinephrine plus norepinephrine excretion
measurements were not significantly different in the study
patients from day to day during the hospitalization period.
Plasma epinephrineandnorepinephrine and totalplasma
catecholamines before exercise were significantly higher in
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pain, six patients became extremely fatigued during and for
up to 60 minutes after the infusion, six experienced dyspnea,
four became dizzy, two felt numbness and two had a panic
attack. Hyperventilation was observed in only two of the
patients. Four patients had cool hands during isoproterenol
infusion and one each had ectopic atrial rhythm and junc-
tional rhythm. None of the control patients developed symp-
toms excluding palpitation during isoproterenol infusion.
Discussion
Increased adrenergic activity. If one accepts the prem-
ise that many patients with mitral valve prolapse syndrome
were previously considered to have irritable heart, soldier's
100 20050
10-+---,---,---,-
25 100 200 25 50
SODIUM (mEq/24hrl
Figure 3. An inverse relation is present between 24 hour urinary
norepinephrine (NE) and sodium (Na+) excretion in patients with
the mitral valve prolapse syndrome (MVPS) but not in control
subjects.
N.S.
I
p<O.OI
p<O.OI
2pg/min
• MVPS
llliillJ (n: 16)
N.S.
p<O.OI
N.S.
p<O.OI
p<O.OI
DCONTROL(n: 12)
0.5 pg/m in I jJg/m in
60
20
40
20
60
+20
6PP
(mmHg)
40
60
QT - QS2
(ms)
6HR
(beats/min)
40
Figure 4. Effect of isoproterenol infusions on heart rate (HR),
pulse pressure (PP) and QT-QS2 relation. Changes (,0;) in heart
rate and QT-QS2 with each isoproterenol infusion were signifi-
cantly greater in patients with mitral valve prolapse syndrome
(MVPS) compared with control subjects; changes in pulse pressure
were not different in patients with mitral valve prolapse compared
with control subjects. N.S. = not significant.
O+---r--f=_L..-...a;:;;:;;a.---,-........L:=--
- 10
pulse pressure during isoproterenol infusion were not sig-
nificantly different.
QT.QS2 relation (Fig. 4). Changes in QT-QS2 relation
during isoproterenol infusion were dose-related. Before is-
oproterenol infusion, the QS2 interval was greater than the
QT interval. During an infusion of 0.5 p,g/min, the QS2
interval was almost equal to the QT interval; during a 1.0
p,g/min infusion, it was significantly shorter than the QT
interval (p < 0.01) (QT prolongation relative to QS2); and
during a 2.0 p,g/min isoproterenol infusion, the QT prolon-
gation relative to QS2 was even greater (p < 0.01). QT-
QS2 values were similar in both groups before isoproterenol
infusion (- 26.5 ± 2.9 versus - 25 ± 3). However, during
isoproterenol infusion, QT-QS2 differences were signifi-
cantly different in patients with mitral valve prolapse com-
pared with control subjects.
The duration of diastolic time before and during each
isoproterenol infusion in symptomatic patients with mitral
valve prolapse and in control subjects is shown in Figure
5. Before isoproterenol infusion, the diastolic time per beat
and per minute was the same in patients with mitral valve
prolapse and control subjects. Diastolic time per beat and
per minute decreased significantly in both groups (p < 0.05)
during isoproterenol infusion. However, the decrease in di-
astolic time with each isoproterenol infusion was signifi-
cantly greater in the patients than in the control subjects.
Symptoms. Isoproterenol infusions reproduced symp-
toms in 14 of 16 symptomatic patients with mitral valve
prolapse. Infusion of saline solution did not reproduce the
symptoms. All the symptoms produced by isoproterenol
disappeared during saline infusion. Patients usually were
not aware if saline solution or isoproterenol was infused.
Symptom reproduction during isoproterenol infusion was
dose-related. Three of 16 patients developed symptoms with
a 0.5 p,g/min infusion,S of 13 developed symptoms with
a 1.0 p,g/min infusion and 9 of II developed symptoms
with a 2.0 p,g/min infusion. Seven patients experienced chest
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Figure 5. Effect of isoproterenol infusions on diastolic time per
beat (upper panel) and per minute (lower panel). The decrease
in diastolic time with each isoproterenol infusion was significantly
greater in patients with mitral valve prolapse syndrome (MVPS)
than in control subjects.
heart , systolic gallop sounds or neurocirculatory asthenia ,
then physicians have been attempting to unravel the basis
for symptoms for more than a century ( I) . Throughout the
earlier studies (10,12) , metabolic factors , autonomic dys-
function and sympathetic nervous system hyperactivity were
all considered as possible causes or mechanisms for symp-
toms in this disorder.
Fraser and Wilson (27) , working in the Heart Section at
the Military Hospital, Hampstead , England during World
War I, investigated the sympathetic nervous system in the
" irritable heart of soldiers" in order to better understand
the mechanism by which symptoms were produced . Minute
doses of intravenous adrenalin and apocodeine produced
greater heart rate and blood pressure responses and symp -
toms in their patients with irritable hearts than in control
subjects , which led to the conclusion that in some respects
the sympathetic nervous system was " relatively unstable
(in the irritable heart patients) in that it appears to be more
susceptible to the stimulating and depressing influences re-
specti vely of these drugs" (27).
Peabody and his colleagues (28), at the U.S. Army Gen-
eral Hospital No .9, Lakewood, New Jerse y, evaluated the
effects of the intramuscular injection of epinephrine in sol-
diers with irritable heart using the Goetsch test (28 ,29). A
positive reaction after 0.5 cc of I: 1,000 epinephrine admin-
istration was described as " production of an earl y rise in
the systolic blood pressure of greater than 10 rnrn Hg (10
to 50) or the pulse rate of over 10 or 15 points accompanied
by the production of rather typical symptoms, such as flush-
ing, sweating , increased vascular pulsation, increased tremor
of the hands and often of the arms, restlessness and more
or less marked general nervousness" (28). Sixty-five pa-
tients in the irritable heart group were compared with control
subjects; 60% of the patients had a positive Goetsch test ,
with a doubtful or suggestive result in an additional 10%.
A subgroup of 12 patients had electrocardiograms taken
during the provocative test; 10 of these had symptoms (diz-
ziness , blurred vision , palpitation and precordial pain) that
" bore a close resemblance to the symptoms prominent in
their histories. " Peabody et at. (18) concluded "it is dis-
tinctly interesting, therefore, that so large a proportion should
be hypersensitive to epinephrine. and one should at least
consider carefully whether an unusually excitable sympa-
thetic nervous system may not play a part in determining
their condition. "
The results of our present study show that symptomatic
patients with mitral valve prolapse with high rest adrenergic
tone have hypersensitivity to isoproterenol administration
as manifested by dose -related reproduction of symptoms.
greater heart rate response , shorter diastolic time and greater
QT interval prolongation relative to QSz interval when com -
pared with control subjects. Increased 24 hour urinary ep-
inephrine and norpinephrine excretion and high plasma cate-
cholamines in symptomatic patients with mitral valve prolapse
have been reported previously from this and other institu-
tions (9 , 10).
Adrenergic receptors. The precise explanation for hy-
perresponsivene ss to adrenergic stimulation in our patients
with mitral valve prolapse syndrome is not well understood .
According to the receptor theory , the number of active ad-
renergic receptors should be low in the presence of high
catecholamines, and the response to adrenergic stimulation
should be diminished (26 ,30-33). The hyperresponse to
isoproterenol infusion in our patients would suggest in-
creased beta-receptor function . If beta-receptor function is
increased, then either a defective autoregulatory mechanism
at the catecholamine receptor level or transient increases of
plasma catecholamines during the day may be responsible
for this phenomenon. The observation that the number of
active beta-adrenergic receptors increases with short dura-
tion (up to 60 minutes) of isoproterenol infusion (34) and
our previous observation that the excretion of urinary epi-
nephrine and norepinephrine decreases significantly during
the night (10) support the hypothesis that symptomatic pa-
tients with mitral valve prolapse have frequent . transient
and possibly inappropriate increases of catecholamines dur-
ing the day with activit y, postural changes and stressful
situations. Thus , an inappropriate increase of endogenous
catecholamines during isoproterenol infusion might be re-
sponsible for the hypersensitivity noted during isoproterenol
infusions . Nevertheless , the precise catecholamine-receptor
n CONTROL
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•
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inter-relation in symptomatic patients with mitral valve pro-
lapse has yet to be defined.
Sodium excretion. Low sodium excretion in sympto-
matic patients with mitral valve prolapse has not been ob-
served previously. Urinary sodium excretion appears to be
inversely related to norepinephrine excretion (35-37). The
low urinary sodium excretion in the present study may be
secondary to preferential low sodium intake (38,39), Symp-
tomatic patients with mitral valve prolapse may consume
less sodium and thus excrete less sodium than the control
subjects. Catecholamine levels may be influenced by the
amount of sodium intake. The cause and effect basis for
low sodium-high catecholamine excretion was not estab-
lished, however, in the present study and obviously requires
further evaluation.
Electrical systole-electromechanical systole relation.
The duration of electrical systole (QT) in normal subjects
is shorter (mean ± 1 standard deviation = - 26 ± 13 ms)
and parallels the duration of electromechanical systole (QSz)
throughout the normal range of rest heart rate (40,41). The
QT-QSz intervals represent a basic cardiac electrical-me-
chanical relation; synchrony or parallel behavior appears to
be a normal phenomenon. Dyssynchrony of these intervals
as a response to adrenergic stimulation in symptomatic pa-
tients with mitral valve prolapse is an interesting observation
because this electrical-mechanical dyssynchrony may be re-
lated to the production or occurrence of arrhythmias. Animal
studies by Brooks et al. (42) indicated that the autonomic
nervous system exerted a substantial influence on the pro-
tective zone in the cardiac cycle, and that these effects were
mediated largely by the action of catecholamines released
at localized myocardial sites. Spontaneous transient appro-
priate or inappropriate increases in catecholamines during
daily activities or stressful situations in patients with mitral
valve prolapse syndrome may produce transient QT pro-
longation relative to the QSz interval. To further support
this postulate, our earlier studies (l0) showed that 24 hour
catecholamine excretion and frequency of premature ven-
tricular beats were parallel, and both decreased significantly
at night (p < 0.001). Beta-adrenergic blockade has been
shown to abolish QT prolongation relative to QSz produced
by isoproterenol infusion in normal subjects (19). The po-
tential role of beta-blockade in abolishing QT prolongation
relative to QSz and ventricular irritability in symptomatic
patients with mitral valve prolapse has yet to be defined.
Diastolic time. Diastolic time has a nonlinear relation
with heart rate. Therefore, small changes in heart rate may
result in significant changes in diastolic time (20). The di-
astolic time during isoproterenol infusion was significantly
shorter in patients with mitral valve prolapse compared with
control subjects. This was due to the greater increase in
heart rate. These changes in diastolic time under certain
circumstances may be of clinical significance because the
greater proportion of coronary blood flow occurs in diastole
and subendocardial flow is almost totally diastolic (43). A
sudden significant decrease in diastolic time may result in
subendocardial ischemia (44,45). Spontaneous or inappro-
priate sinus tachycardia in patients with mitral valve pro-
lapse results in a significant decrease in diastolic time, which
under certain conditions may produce subendocardial is-
chemia (46,47).
Mitral valve prolapse-mitral valve prolapse syn-
drome. The cause of adrenergic hyperactivity and hyper-
responsiveness to adrenergic stimulation in symptomatic pa-
tients with mitral valve prolapse is not well understood. The
relation or association between the anatomic entity (mitral
valve prolapse) and the mitral valve prolapse syndrome (an-
atomic mitral valve prolapse and the symptom complex)
requires further definition. An independent, biochemically-
mediated anxiety state existing in an individual with the
anatomic entity (mitral valve prolapse) is one potential ex-
planation for the syndrome. Equally plausible is that the
anatomic entity (mitral valve prolapse) is a specific marker
in certain individuals for the constitutional, neuroendocrine-
cardiovascular process that is currently designated as the
mitral valve prolapse syndrome,
In conclusion. symptomatic patients with mitral valve
prolapse and high rest adrenergic tone have hypersensitivity
to isoproterenol infusion as manifested by reproduction of
symptoms, greater heart rate response, shorter diastolic time
and greater QT prolongation relative to the QSz interval
compared with control subjects. Stress-mediated or acti-
vated biochemical mechanisms that alter adrenergic tone
may provide a basis for the multiple symptoms in patients
with mitral valve prolapse syndrome.
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